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1. INTRODUCTION 
 
The biology of a cancer cell is largely driven by the pattern of gene 
expression within that cell. Since a key point of control of gene expression is 
the activation state of transcription factors, it is likely that a small number of 
transcription factors may represent a central convergence point in cancer 
pathogenesis. One such protein is STAT3, a member of a family of seven 
genes thet encode proteins coupling signaling events at cell surface with gene 
regulation (Frank D. A., 2007). 
The STAT family of cytoplasmic latent transcription factors consists of seven 
members: STAT-1-4, STAT-5a, STAT-5b, and STAT-6. STAT-3 activation 
results in expression of genes that control cell proliferation, survival, 
differentiation, and development. It was first identified in 1994 as a DNA-
binding factor that selectively binds to the IL-6-responsive element in the 
promoter of acute-phase genes from IL6-stimulated hepatocytes. The Stat3 
cDNA was cloned in the same year and encodes an open reading frame of 
770 amino acids resulting in a protein of 88 kDa (Akira et al., 1994).STAT-3 
was also independently identified as a DNA-binding protein in response to 
epidermal growth factor (Bharat B. Aggarwal et al, 2009).  
 
1.1 Domain structure of STAT-3 protein 
 
STAT proteins are 750–850 aminoacids long and have a common 
structure of six functionally conserved domains.  
The N-terminal domain (NTD) was shown to be important for 
dimerization of unphosphorylated STATs monomers and for the 
tetramerization between STAT1, STAT3, STAT4 and STAT5 on promoters 
with two or more tandem STAT binding sites. Xu and colleagues (Xu et all, 
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1996) proposed that these tetramer complexes are able of transcribing 
selective target genes to which they bind weakly through recognition of non-
consensus regions. This domain also plays a role in promoting interactions 
with other proteins, namely transcriptional co-activators such as CREB 
binding protein (CBP)/p300. Additionally, it is important for nuclear import 
and deactivation of STATs involving tyrosine de-phosphorylation (C. 
Mertens, 2006).  
The four α-helices coiled–coil domain (CCD) is known to be involved 
in interactions with other proteins, such as IFN regulatory protein 9 (IRF-
9/p48) with STAT1 (Zhang X., 1999) and c-JUN with STAT3 (Horvath 
C.M., 1996). STATs coiled–coil domain is also thought to participate in the 
negative regulation of these proteins. The STAT3 coiled–coil domain has 
been implicated in the recruitment and binding of STAT3 to the interleukin 6 
(IL-6) and epidermal growth factor (EGF) receptors  (T. Zhang et all, 2000) 
and in its nuclear translocation upon treatment with EGF, or IL-6 (Ma J., 
2003).  
The DNA-binding domain (DBD) is highly conserved.  Small 
differences in the amino acid sequences of this domain across different STAT 
molecules often determine binding to and transcription of distinct genes by 
each STAT (Boucheron C., 1998). This domain is also involved in nuclear 
translocation of activated STAT1 and STAT3 phosphorylated dimers upon 
cytokine stimulation.  
The α-helical linker domain (LD) links the DNA-binding and SH2 
domains and is important for the transcriptional activation of STAT1 in 
response to IFN-γ (Yang E., 1999). It also plays a role in protein–protein 
interactions, for instance, between STAT3 and gene associated with retinoid-
IFN-induced mortality 19 (GRIM19), a negative regulator of transcription 
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(Lufei C., 2003; Zang Y., 2003). This STAT domain has also been implicated 
in constitutive nucleocytoplasmic shuttling of unphosphorylated STATs in 
resting cells, an effect that is mediated through interactions with nuclear pore 
proteins (Marg A., 2004). The most well conserved domain in the structure of 
STATs, the SH2 domain (SH2D), is necessary for receptor association and 
tyrosine phosphodimer formation. This domain precedes the transactivation 
domain located on the C-terminus. Some residues within this domain may be 
particularly important for some cellular functions mediated by the STATs.  
The C-terminal domain is the one that differs the most among STATs 
and functions as a transactivation domain (TAD) (Levy D.E., 2002). The 
conserved tyrosine residue present on all STAT proteins in the C-terminus is 
crucial for dimerization. In addition, with exception of STAT2 and STAT6, 
all other STATs have in the TAD a conserved serine residue. 
Phosphorylation of a single serine (S727) in the C-terminal transactivation 
domain of STAT3 allows for the maximal activation of transcription of 
responsive genes. (Z. Wen, 1995; Santos C.I., 2011). In the canonical STAT3 
signaling pathway, activation of cell surface receptors by growth factors and 
cytokines induces the specific phosphorylation of receptor tyrosine residue to 
create docking sites for the recruitment of latent cytoplasmatic STAT3.  
STAT3 docking to receptor phosphotyrosine (pY) sites is mediated through 
its SH-2 domain. The binding of STAT3 at receptor pY sites leads to the 
phosphorylation of a specific tyrosine residue of STAT3 (Y705) in the C-
terminal domain, and this phosphorylation activates STAT3. The 
phosphorylation of STAT3, in turn, promotes homodimerization, or 
heterodimerizes with STAT-1, wherein the SH-2 domain of each monomer 
interacts with the Y705 residue of its partner. STAT3 dimers translocate to 
the nucleus where they bind to specific DNA response elements, such as the 
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TTN4-5AA sequence (where N refers to any nucleotide base), in the 
promoter regions of responsive target gene to regulate their transcription 
(Emily C. Brantley 2008). 
 
1.1.1 The STAT3 isoforms α and β 
 
An important factor determining STAT3 functional heterogeneity is probably 
the existence of two alternatively spliced isoforms: the fulllength STAT3α 
and the truncated STAT3β, which lacks the C-terminal activation domain and 
is generally considered a dominant negative form (Caldenhoven E., 1996, 
Schaefer T.S, 1995) (Fig.1).  To assess the specific functions of STAT3α and 
STAT3β, Maritano D. et al. generated mice that can produce only one 
isoform or the other. They confirmed that STAT3β is not required for 
viability but is involved in inflammation. In contrast, STAT3α-deficient mice 
died within 24 h of birth, showing that this isoform is required for postnatal 
function(s) but that STAT3β can rescue the embryonic lethality of a complete 
STAT3 deletion. Indeed, their data indicate that STAT3β is not a dominant 
negative factor, as it can activate specific STAT3 target genes. However, 
STAT3α has nonredundant roles in modulating IL-6 signaling and mediating 
IL-10 functions. A question was how does STAT3β, which lacks the 
transcription activation domain responsible for recruiting coactivators such as 
p300-CBP, activate transcription? This isoform was first isolated by a two-
hybrid screen using c-Jun as a bait and cooperates with this factor to activate 
transcription of the acute-phase α2-macroglobulin and α1-antichymotrypsin 
gene promoters through STAT3 and transcription factor AP-1 binding sites. 
Interaction with c-Jun requires the STAT3 Nterminal coiled-coil region, 
present in both the STAT3α and the STAT3β isoforms (Zhang X., 1999; 
Zhang X., 2001). In addition, STAT3α and STAT3β can partecipate equal 
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well in the formation of a ternary complex (enhanceosome) involving the 
STAT3 and AP-1 sites plus two downstream AT-rich regions on the α2-
macroglobulin promoter33. Therefore, although only STAT3α might be able 
to activate specific target genes on its own through the direct recruitment of 
coactivators, both STAT3α and STAT3β may be able to activate a common 
subset of target genes by participating in the formation of higher hierarchy 
complexes, which in turn provide the optimal surface to recruit coactivators 
and the basal transcriptional machinery. Depending on promoter 
composition, specific subsets of target genes might then be solely responsive 
to STAT3β. Global expression profiling coupled with promoter composition 
analysis may lead to understanding of the rules dictating activation by the 
two isoforms (Maritano D. et al, 2004). 
 
 
 
 
 
 
 
 
Fig.1: Schematic structure of STAT proteins. A) The domain structure of full-length Stat3 protein (designated either 
Stat3 or Stat3α). B) as compared with Stat3α, the Stat3β splice variant has an COOH-terminal deletion, resulting in 
an altered open reading frame with the addition of seven new amino acids downstream of the deletion, and loss of 
the TAD domain. This naturally occurring truncated isoform still dimerizes and binds to DNA. Y, critical 
phosphotyrosine in all STATs (amino acid 705 in Stat3); S, critical phosphoserine in some STATs (amino acid 727 
in Stat3). (Buettner R., 2002). 
 
 
 
1.2 STAT3 activation pathways 
 
Various growth factors that have been linked to tumor cell 
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proliferation have been found to activate STAT3. EGF signaling, which has 
been linked with proliferation of almost 30% of all tumor cells, has been 
shown to mediate its effect through activation of STAT3. Similarly, IL-6, 
which has been linked with proliferation of multiple myeloma, renal cell 
carcinoma, prostate cancer, and other cancers, has been shown to mediate its 
effect through activation of STAT3. Moreover, several other cytokines have 
been shown to activate STAT3. These include growth hormone, transforming 
growth factor-α (TGF-α), oncostatin M, thrombopoietin, platelet-derived 
growth factor (PDGF), IL-5, IL-6, IL-9 IL-10, IL-12, IL-22 and leptin. 
Certain chemokines, such as macrophage inflammatory protein 1α and 
RANTES (regulated upon activation of normal T cell expressed and secreted) 
also have been shown to activate STAT3. Besides growth factors and 
cytokines, other factors that activate STAT3 include oxidative stress, tobacco 
chewing, hepatitis C virus, ultraviolet B, lipopolysaccharide, osmotic shock 
and progestins. Cytokines and growth factors initiate STAT-3 signal 
transduction when they bind to their receptors and activate intracellular 
kinases. STAT-3 is tyrosine phosphorylated by three types of kinases (Fig. 
2):  
- receptor tyrosine kinases such as EGFR, FGF receptor (FGFR), or 
platelet-derived growth factor receptor 
- Janus kinase (JAK) family members, which are constitutively bound 
to the cytoplasmic tails of cytokine receptors 
- non-receptor associated tyrosine kinases, including Ret, Src family 
(hck, src), or the Bcl-Abl fusion protein.  
JAK2 is one of the major mediators of STAT3 phosphorylation. JAK 
proteins are autophosphorylated and transphosphorylated and phosphorylate 
one of four tyrosine residues on the intracellular portion of gp130 subunit. 
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JAK protein activation results in downstream signal transduction through 
both the MAPK and STAT-3 pathways.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: STAT3 signaling (Bollrath J., 2009) 
 
 
 
1.3 Negative regulators of STAT3 
 
Under normal conditions, both the amplitude and duration of 
receptor-induced STAT3 activation are tightly controller by a variety of 
endogenous protein regulators. Peak STAT3 phosphorylation occurs within 
approximately 30-60 min of exposure to cytokine, and even in the presence 
of continuous cytokines, STAT3 activation decreases over several hours. 
Since continuous STAT3 activation can lead to neoplastic transformation, it 
is clear that the feedback mechanisms attenuating STAT3 function must be 
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efficient and multi-layered.  
 
1.3.1 STAT-3 inhibition by SOCS-3 
Suppressors of cytokine signaling (SOCS) proteins down-regulate the 
upstream kinase activity responsible for STAT3 phosphorylation. SOCS-3 is 
a member of the SOCS protein family, which comprises seven SOCS 
proteins (SOCS-1 through SOCS-7) and cytokine inducible SH2 domain 
containing protein. The cytoplasmatic, inducibly expressed SOCS proteins 
attenuate STAT activity by inhibiting upstream JAK activation in a classic 
negative feedback loop. Activated STAT-3 induces the expression of SOCS-
3, which subsequently inhibits STAT-3 signaling by binding to and 
attenuating the signal transduction of gp130-related cytokine receptors and 
their associated JAK kinases.  
 
1.3.2 STAT-3 inhibition by PIAS Proteins and Protein Tyrosine 
Phosphatases. 
The protein inhibitors of activated STATs (PIAS) proteins and protein 
tyrosine phosphatases target STAT proteins directly. Several protein tyrosine 
phosphatases (PTPs) have been implicated in the termination of STAT3 
signaling, including SHP-2, PTP1B, PTPεC, TC45, and SHP-1. SHP-2 is 
ubiquitously expressed, and like SHP-1, contains two N-terminal SH-2 
domains and a C-terminal PTP domain. SHP-2, by virtue of its two SH-2 
domains, associates with pY-sites of growth factor receptors, cytokine 
receptors, gp130, JAKs, members of the Src family of tyrosine kinases 
(SFKs), and STAT3. SHP-2 may in turn become phosphorylated by RTK 
activities, JAK1, JAK2, and SFKs. All of the pY components of STAT3 
signaling pathways are potential substrates for PTPs. Because only STAT3 
dimers bind to DNA, the nuclear PTP TC45 may be important in the 
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termination of STAT3-mediated transcriptional activation. The highly 
conserved PIAS family of proteins includes PIAS1, PIAS3, PIASx, and 
PIASy. Except for PIAS1, each protein has two isoforms, and PIAS3 
regulates STAT-3. In contrast to the inducibly expressed SOCS proteins, 
PIAS proteins are constitutively expressed in the nucleus and mediate 
transcriptional repression by directly interfering with the binding of STAT 
proteins and other transcription factors to their target DNA sequenze. All 
PIAS proteins contain a zinc ring finger domain, an NH2-terminal LXXLL 
motif, a COOH-terminal acidic domain, a serine/threonine–rich domain, and 
a recently discovered PINIT motif that is involved in nuclear retention. PIAS 
proteins inhibit STAT transcriptional activity by interfering with DNA 
binding via their NH2-terminal domains. PIAS proteins also recruit 
transcriptional corepressors such as histone deacetylases to target gene 
promoters to inhibit transcription. Furthermore, PIAS proteins influence the 
activation status of transcription factors by directly modifying the proteins 
themselves. Some PIAS proteins, including PIAS3, exhibit E3-SUMO (Small 
Ubiquitin-like MOdifier) ligase activity and SUMOylate a variety of 
transcription factors, including STAT3, but it is unclear whether sumoylation 
contributes to the inhibition of STAT3 function.  
 
 
1.4 STAT3 target genes 
 
STAT-3 is an oncogenic protein that is constitutively activated in 
many human cancers. For instance, in 30–60% of primary breast cancers, 
STAT-3 is constitutively active. Constitutive activation of STAT-3 has also 
been reported in several other primary cancers, in tumor cell lines, and in 
many oncogenetransformed cells. Inactivation of STAT-3 in most of these 
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cell lines leads to inhibition of cell proliferation. The evidence below shows 
that STAT-3 activation is intimately connected with all aspects of 
tumorigenesis. Stat3 target genes have been identified and include regulators 
of crucial steps in oncogenesis such as proliferation and survival of tumor 
cells, their migration and invasion properties, their potential to induce 
angiogenesis and to evade the host immune response. Stat3 is a 
transcriptional activator of the Mcl-1, Bcl-XL and Survivin genes, which act 
as suppressors of apoptosis. Stat3 regulates expression of c-Myc and Cyclin 
D1 which are proliferation-promoting genes as well as vascular endothelial 
growth factor (VEGF), which favor angiogenesis. P53 is negatively regulated 
by Stat3, inhibiting its tumor suppressor activity. Tumor immune evasion is 
enhanced through Stat3-mediated reduction of the secretion of pro-
inflammatory cytokines and chemokines. STAT-3 activation regulates the 
expression of matrix metalloproteinase (MMP-2 and MMP-1), which then 
mediate tumor invasion and metastasis. STAT-3, however, is also known to 
upregulate tissue inhibitors of metalloproteinase (TIMP-1), a cytokine known 
to block metalloproteinases and decrease invasiveness in certain cancer cell 
types. STAT-3 also controls the expression of the MUC1 gene, which can 
mediate tumor invasion. However, genome-wide analysis of the effects of 
STAT3 activation reveal a potentially more complex transcriptional network. 
A large number of genes that are up-regulated early following STAT3 
activation are transcription factors themselves including junB, egr1, KLF4, 
bcl-6, and NFIL3, suggesting that STAT3 can regulate broad programs of 
gene expression. Interestingly, some of the previously reported STAT3 
targets such as cyclin D1 were not up-regulated during this time frame. This 
observation suggests that STAT3 may act upstream of several transcription 
programs such that different targets may be activated or repressed at distinct 
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time points following STAT3 activation. Such interplay of transcription 
factors and the potentially transient activation of specific targets may 
significantly complicate the identification of key targets. Despite this 
potential difficulty, microarray analysis of STAT3-mediated transcriptional 
changes after longer periods of activation identified several genes involved in 
several important pathways implicated in oncogenesis. The validation of such 
targets represents an important new avenue of research on a relatively under-
explored aspect of STAT3 biology. 
 
 
1.5 STAT3 and its Coregulators  
 
One important question to be resolved is what molecular basis 
governs STAT3 gene activation, which cofactors are associated with the 
transcription factor on its target genes, and how is the coregulator exchange 
process used to integrate dynamic changes in the signaling network and 
transmit these changes to the chromatin? It was established an essential role 
of NH2 -terminal acetylation of STAT3 in protein-protein interaction 
resulting in stable formation of the enhanceosome complex, target gene 
expression, and nucleoplasmic shuttling (Giraud S. et al, 2004). Among the 
most coactivators described in the literature (Fig. 3) there is the CBP/p300 
protein, requied by many different transcription factors for its ability to 
acetylate histones and other proteins. The histone acetylases allow greater 
access to DNA but also function as bridging factors to the transcriptional 
machinery. In the table below are show the most known coactivators were 
reported in the literature, but many question are still unclear: are the 
interactions between two proteins the same in all enhanceosomes? Stated 
another way, how many enhanceosomes can be built from a limited 
repertoire of participants? 
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Type Name Functions Description 
Co-activator CBP/p300 Histone acetylases Wang R. et al [2005] 
 NcoA/SRC1a Histone acetylases Giraud S. et al [2002] 
 BRG1 
Component of the 
SWI/SNF chromatin-
remodeling complex 
Giraud S. et al [2004] 
 Cdk9 
Component of the 
elongation factor 
PTEFb 
Giraud S. et al [2004] 
 c-Jun/c-Fos Transcription factor Lerner L. et al [2003] 
 Oct-1 Transcription factor Lerner L. et al [2003] 
 APE-1/Ref-1 Protein in the DNA base-excision repair Sutapa R. et al [2010] 
 ERp57 Protein disulfide isomerase 
Chichiarelli S. et al 
[2010] 
 AR Androgen Receptor Miguel de F. [2003] 
    
Co-repressor Tip60 HAT activity Xiao H. et al [2003] 
 
PPAR-γ 
Peroxisome 
Proliferator-Activated 
Receptor-γ 
Wahn H. et al [2005] 
 
KAP1/TIF1b 
Corepressor for the 
Kruppel-associated 
box-domain-containing 
zinc- finger proteins 
Tsuruma R. et al 
[2008] 
 
Fig.3 : Coactivators and Corepressor of STAT3 reported in literature 
 
 
1.6 Nuclear import of STAT3 
 
The presence of STAT3 in the nucleus and the cytoplasm under basal 
conditions suggests a constant shuttling of STAT3 between the two cellular 
compartments. Unlike other STATs, such as STAT1 and STAT2, which 
accumulate in the nucleus only following their phosphorylation, STAT3 can 
enter the nucleus independently of its phosphorylation. The mechanism 
underlying these differences relates to the involvement of distinct importins 
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used by STATs for their nuclear import. For instance, the phosphorylation of 
the nuclear localization signal of STAT1 is a prerequisite for its interaction 
with importin α-5 and subsequent nuclear import. In contrast, STAT3 binds 
constitutively to importin α-3 and α-6. Although the shuttling of STAT3 in 
and out of the nucleus seems independent of its phosphorylation, the strict 
requirement for phosphorylation for the transcriptional activation of STAT3 
remains a controversial topic. Initially, the finding that introducing cysteine 
residues into the COOH terminus of STAT3 (generating the STAT3C 
mutant) is sufficient to promote the constitutive activation of STAT3 led to 
the hypothesis that these cysteines promote the formation of disulfide bonds 
between unphosphorylated monomers. This suggested that although 
phosphorylation could trigger dimerization, it was not necessary for 
activation. However, because mutation of the critical tyrosine residues within 
STAT3C abolished its transcriptional activity, it was suggested that STAT3 
may be phosphorylated and dephosphorylated at a low rate in the absence of 
cytokine and that introducing cysteine residues simply acts to trap 
spontaneously phosphorylated dimers. Conversely, another study reported 
that STAT3 with a mutation of Tyr705 retains transcriptional activity  but 
affects a distinct subset of genes compared with wild-type STAT3. 
Nevertheless, the nuclear translocation of STAT3 in the absence of 
phosphorylation raises the question as to whether unphosphorylated STAT3 
has a role in the nucleus. The finding that the nuclear tyrosine kinase breast 
tumor kinase phosphorylates STAT3 raises the possibility that such nuclear 
rather than cytoplasmic phosphorylation of STAT3 acts as a rapid activation 
mechanism and may contribute to its oncogenic effect (Doris Germain, 
2007). 
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1.7 Cytoplasmic role of STAT3.  
 
Although most attention has been focused on the transcriptional 
function of STAT3, the recent discovery of cytoplasmic partners of STAT3 
has raised the possibility of unsuspected new roles for this protein in the 
cytoplasm. One of the first clues was the observation that p130CAS, an 
adaptor protein that localizes to focal adhesion sites and which assembles 
with focal adhesion kinase and its partner paxillin, was hyperphosphorylated 
in STAT3- deficient keratinocytes. Further, phosphorylated STAT3 was 
found to localize to the migrating protrusions and focal adhesions in 
migrating cells. These observations therefore suggested a transcription-
independent function of STAT3 in regulating cell migration. More recently, 
stathmin, a tubulin binding protein, which promotes microtubule 
depolymerization, was identified as a binding partner of STAT3. Although 
stathmin did not seem to regulate STAT3 transcriptional activity, 
unphosphorylated STAT3 was found to prevent stathmin from binding to 
microtubules, thereby promoting microtubule polymerization and cell 
migration. Thus, STAT3 can affect migration both via its transcriptional 
regulation of genes involved in cell migration and also through its 
transcription-independent interactions with focal adhesion molecules and its 
inhibition of stathmin. 
 
 
1.8 STAT3 in the mitochondria 
 
 Recently, STAT3 was shown to play an unconventional role in 
mitochondria, although it does not contain a mitochondrial targeting 
Introduction 	  
	  15	  
sequence. Reconstitution of STAT3- deficient cells with different STAT3 
mutants specifically targeted to the mitochondria revealed that mitochondrial 
STAT3 is sufficient to modulate respiratory chain activity and that 
phosphorylation on serine 727 and a monomeric conformation play a crucial 
role in this process (Nicole Büchner, 2010). Mitochondrial STAT3 
(mSTAT3) appears to sustain Electron Transport Chain basal activity under 
normal or RAS-transformed conditions, supporting RAS-dependent 
oncogenic transformation, and it was suggested to act as a negative regulator 
of the Mitochondrial Permeability Transition Pore (MPTP), thus mediating 
cardioprotection after ischemia/reperfusion (Demaria M., 2011; Figure 4). 
Ras mediated transformation in vitro and tumor growth in mice were 
impaired in STAT3-deficient cells. Mutational analysis demonstrated that the 
N-terminal DNA binding domain, the Src homology 2 (SH2) domain, 
phosphorylation on tyrosine 705, and nuclear localization of STAT3 are 
dispensable for supporting malignant transformation by Ras. In contrast, 
tyrosine phosphorylation and presence in the nucleus are required for 
transformation by the tyrosine kinase oncogene v- Src. This newly 
discovered function of STAT3 was ascribed to its mitochondrial localization 
accompanied by augmentation of respiratory chain activity, particularly that 
of complex II and V, and a dependence on phosphorylation of serine 727. 
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Fig. 4: Converging roles of nuclear (n) and mitochondrial (m) STAT 3  
(Demaria  M. and Poli V., 2011). 
 
 
 
 
1.9 Unphosphorylated STAT3 
 
The presence of STAT3 in the nucleus and the cytoplasm under basal 
conditions suggests a constant shuttling of STAT3 between the two cellular 
compartments. For a long time, the tyrosine phosphorylation of STATs by 
ligand activated receptors was thought to be an obligatory requirement for 
dimerization in an active conformation, nuclear import, and transcriptional 
activation. More recently it has been shown that nonphosphorylated STATs 
shuttle between the cytoplasm and the nucleus at all times in a costitutive 
manner and that also these nonphosphorylated STATs (U-STATs) can be 
transcriptionally active, either as homodimers or in a complex with other 
transcription factors. However, these nonphosphorylated STATs regulate a 
different set of target genes than their phosphorylated counterparts. Major 
mechanisms of STAT3 activation in tumor cells are autocrine production of 
IL-6 and paracrine activation by IL-6 from stroma and infiltrating 
inflammatory cells. Indeed, circulating IL-6 levels are usually high in cancer 
patients (Giannitrapani et al. 2002). STAT3 activation provides an important 
link between inflammation and cancer. There are several reports that STAT3 
and NFκB interact with each other (Battle and Frank 2002). The expression 
of U-STAT3 is greatly increased in response to their activation, since the 
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STAT3 gene is strongly activated by P-STAT3 dimers, which are formed in 
response to IL-6 and other ligands that activate the gp130 common receptor 
subunit. U-STAT3, induced to a high level due to activation of STAT3 gene, 
binds to unphosphorylated NFκB (U-NFκB), in competition with IκB, and 
the resulting U-STAT3/p65/p50 complex accumulates in the nucleus with 
help of importin-α3, activating a subset of κB-dependent genes (Yang J., 
2008). Since the Y705F mutant of STAT3, which cannot be phosphorylated 
on tyrosine, also activates RANTES expression, this function of U-STAT3 is 
clearly distinct from the absolute requirement for tyrosine phosphorylation 
that enables STAT3 dimers to bind to GAS (gamma-activated site) sequences 
(Wen et al. 1995; Kaptein et al. 1996; Zhang et al. 1999). The full biological 
relevance of the ability of P-STAT3 to increase the intracellular 
concentration of U-STAT3 remains to be established. In the contest of 
cancer, the costitutive tyrosine phosphorylation of STAT3 in many different 
tumori is likely to lead to increased expression of U-STAT3, which in turn 
drives the expression of oncogenes such as MET and MRAS. 
 
 
1.10 STAT3 activation in cancer 
 
Reflecting the potentially important role for STAT3 in cellular 
function, in recent years, a large series of publications has demonstrated the 
costitutive activation of STAT3 in nearly every major human cancer (Frank 
DA., 2003). One question that arises is the mechanism by which constitutive 
STAT activation occurs in a tumor. Under normal physiologic conditions, 
STAT3 activation in response to growth factors is a transient response. This 
reflects the fact that a variety of negative feedback systems exist to rapidly 
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dampen signals leading to STAT activation. Thus, constitutive STAT3 
activation seen in tumors likely reflects not only enhanced activity of a 
tyrosine kinase that can mediate the phosphorylation of STAT3, but also a 
loss or repression of the normal mechanisms that dampen the STAT3 
response. STAT3 can be activated in tumors through increased signaling 
through cytokine receptors, such as the receptor for interleukin-6, which can 
occur through autocrine or paracrine release of this factor. This is likely a 
significant feature in tumors such as multiple myeloma, in which IL-6 has 
long been known to play a pivotal role (Kawano M., 1988; Catlett-Falcone 
R., 1999). However, autocrine activation of STAT3 is also important in 
epithelial cancers such as breast cancer (Li L., 2002) and pancreatic cancer 
(DeArmond D., 2003). In many forms of cancer, increased levels of IL-6 are 
associated with a poor prognosis, and this may reflect enhanced STAT3 
phosphorylation within the tumor cell, although it may also be a marker of 
the physiological stress induced by the presence of an advanced cancer. 
Activation of STAT3 in tumor cells may also obviate the need for external 
growth signals. Thus, costitutive STAT3 activation is associated with IL-6 
independence in animal models of myeloma (Rawat R., 2000) and androgen 
independence in prostate cancer (Lee S.O., 2003). However, as noted, several 
feedback mechanisms are in place to dampen or interrupt STAT activation. 
These findings provide insight into the pathogenesis of these tumors, and 
they also have implications for therapeutic interventions targeting this 
pathway. It is becoming increasingly clear that activating mutations in 
tyrosine kinases are a common occurrence in a range of human cancers, and 
many of these lead directly to STAT3 activation. However, other 
mechanisms of cellular transformation, such as viral carcinogenesis, may also 
make use of STAT3. For example, the core protein of the epatitis C virus, 
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which is associated with the development of hepatocellular carcinoma, 
mediates the tyrosine phosphorylation of STAT3, which is necessary for 
malignant cellular transformation (Yoshida T., 2002). While the mechanism 
for this is unclear, this finding emphasizes the central role played by this 
transcription factor in malignancy. Although tyrosine phosphorylation is 
clearly necessary for the ability of STAT3 to mediate transcriptional 
activation, in many systems maximal activity of STAT3 requires 
phosphorylation of STAT3 on serine 727 as well. There is evidence that 
activation of the EGF receptor through mutation can maximally enhance the 
serine phosphorylation of STAT3, and that this event may be critical to the 
transforming ability of these mutations (Alvarez J.V., 2006)s. In chronic 
lymphocytic leukemia, constitutive serine phosphorylation of STAT3, in the 
absence of tyrosine phosphorylation has been found (Frank D.A., 1997) , 
although it is unclear how this may alter the biology of these cells. It could be 
argued that there are multiple intracellular pathways that can lead to 
malignancy, only one of which involves STAT3. However, increasing studies 
on primary human samples has revealed that a majority of patients with 
common tumors such as cancer of the breast, prostate, and pancreas display 
STAT3 activation (Alvarez J.V., 2005; Wei D., 2003). Furthermore, given 
the central role that STAT3 target genes play in promoting proliferation and 
survival, it is perhaps not surprising that activation of STAT3 is associated 
with a poor prognosis in cancers such as acute myeliod leukemia (Figure 5). 
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1.11 STAT3 and its Post-Translational Modifications (PTMs) 
 
STAT3 protein is regulated by multiple tyrosine kinase and serine 
kinase pathways, and thus sit at a key convergence point where they can 
integrate the effects from different stimuli. Although less well understood 
currently, there is evidence that STAT3 cas also be modulated by post-
translational modifications such as acetylation, glutathionylation, poli-ADP 
ribosylation and SUMOylation. Post-translational modifications (PTMs) of 
nuclear proteins are involved in activating and inactivating critical signaling 
pathways in cellular processes of malignant transformation and progression.  
Thus, the model of diverse pathways converging on STAT3 may be even 
broader than currently appreciated.  
 
1.11.1 Acetylation. 
Function-related posttranslational modifications of STAT proteins in 
response to treatment with cytokine or growth factor include phosphorylation 
of a single tyrosine residue in the short segment and a single serine residue in 
the TAD. However, unphosphorylated or tyrosine-mutated STAT proteins 
can still form dimers and induce transcription (5–8), suggesting that another 
type of regulation contributes to the formation of stable STAT dimers. The 
C-terminal region of STAT interacts with other proteins during signaling or 
transcription. For instance, members of the CREB-binding protein 
(CBP)/p300 family have intrinsic histone acetyltransferase (HAT) activity, 
associate with various STAT family members within both the C-terminal 
TAD and N-terminal domain, and increase STAT activity in transcription. 
There are evidence of Stat3 acetylation on Lys685 site. It resides in the 
highly hydrophilic region between the SH2 domain and TAD and is highly 
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conserved in Stat1, Stat3, Stat4, Stat5a, and Stat5b of different species. Use 
of a prostate cancer cell line (PC3) that lacks Stat3 and PC3 cells expressing 
wildtype Stat3 or a Stat3 mutant containing a Lys685-to-Arg substitution 
revealed that Lys685 acetylation was critical for Stat3 to form stable dimers 
required for cytokine-stimulated DNA binding and transcriptional regulation, 
to enhance transcription of cell growth–related genes, and to promote cell 
cycle progression in response to treatment with oncostatin M (Zheng-long 
Yuan, 2005). 
1.11.1 Redox modification. 
Several reports have highlighted an effect of reactive oxygen species 
(ROS) on STAT3 activity. Although ROS scavengers and inhibitors of NOX 
enzymes generally inhibited STAT3 activity, the otherwise divergent reports 
indicated that the effects of ROS may be tissue specific and manifested at 
several levels (e.g., by their actions on tyrosine phosphatases and Janus 
kinases). The susceptibility of reactive cysteines in proteins to ROS and 
nitrosative stress render them vulnerable to oxidative modification. In most 
cases, low-molecular mass thiols such as glutathione (GSH) can form mixed 
disulfides with oxidized cysteine forms in protein. This process, known as S-
glutathionylation, has emerged as a redox-sensitive posttranslational 
modification that can modulate enzymatic activities, protein folding and 
functions, and protein-protein interactions.  STAT3 itself is susceptible to 
oxidation in cells under oxidative stress and was shown to be modified and 
repressed by cysteine glutathionylation. Xie et al (Xie Y, 2009) showed that a 
small but detectable S-glutathionylation of STAT3 occurred in intact cells 
under basal conditions, and that exogenous oxidant diamide elicited an 
increase in STAT3 S-glutathionylation, which was accompained by reduction 
in IL6-induced tyrosine phosphorylation of this transcription factor, with 
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subsequent impairment in the retention of STAT3 to the nucleus and 
transcriptional activation of target genes. STAT3 contains 14 cysteines, of 
which 5 are conserved in STAT1. The DNA-binding domain (DBD) of 
STAT3 contains up to three reactive cysteines (C418, C426, and C468) with 
one other (C765) present within the C-TAD (Li Li, 2010).  It appear that this 
modification hampers the access of the Tyr-705 region to the STAT3 
recognition site on JAK2. The modifications in a cluster of cysteines in the  
DNA binding domain may down-regulate the transcriptional potency of 
STAT3 in response to diverse stimuli. It is possible that essential 
transcriptional coactivators of STAT3 may also be the target of dynamic 
redox control through S-glutathionylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5: Tumor that express constitutively active STAT3, activators of STAT3, genes regulated by STAT3, and 
inhibitors of STAT3. 
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1.12 STAT3 in human prostate cancer 
 
Constitutive STAT activation occurs frequently in a variety of human 
tumor cell lines and primary human tumors including leukemias, lymphomas, 
multiple myeloma, head and neck cancer, and breast cancer  because 
signaling by Stat3 protein participates in regulating the processes of cell 
growth and survival during oncogenesis. Stat3 is constitutively activated with 
high frequency in prostate adenocarcinomas compared with matched adjacent 
nontumor prostate tissues. Prostate cancer (PCa) cell growth was stimulated 
by IL-6, accompanied by activation of STAT3. Dhir et al demonstrated that 
cells derived from both rat and human prostate cancer have costitutively 
activated STAT3, and that STAT3 activation is associated with malignant 
potential (Ni Z., 2000). In the initial stage, PCa is dependent on androgens 
for growth, which is the basis for androgen-deprivation therapy (ADT). 
However, in most cases, prostate cancer progresses to a hormone refractory 
phenotype for which there is no effective therapy available at present. The 
development of androgen escape is therefore one of the most significant 
events in the progression of prostate cancer, resulting in a greater risk of 
morbidity, and reduced survival. The androgen receptor (AR) is required for 
prostate cancer growth in all stages, including the relapsed, “androgen-
indipendent” tumor in the presence of very low levels of androgens (Kaarbø 
M., 2007). Failure of ADT, as in hormone-resistant prostate cancer, was 
therefore logically linked to modification of the action of the AR, as 
mutations, AR gene amplifications, post-translational modification of the 
AR, via phosphorylation at specific sites. In recent years it has become 
increasingly apparent that androgen escape may also involve mechanisms 
that do not directly modify the AR, but may also involve the action of AR 
coactivators or pathways independent of the AR. A way by which AR 
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cofactors can influence the development of androgen escape is not as well 
established and involves binding of cofactors to the AR, resulting in AR 
translocation to the nucleus. An example of this is STAT3. In vitro studies 
show that interleukin-6 activation of the JAK/STAT3 pathway is 
accompanied by transition from androgen-sensitive to -insensitive prostate 
cancer cell growth (Fig. 6). Levels of activated STAT3 are significantly 
higher in the hormone-refractory prostate cancer cell lines (DU145 and PC3) 
than in hormone-sensitive cell lines (LNCaP cells). In LNCaP cells the 
activated dimer of STAT3 binds ligand-free AR before entering the nucleus, 
therefore facilitating the translocation of AR to the nucleus in the absence of 
androgens. The AR/STAT-3 complex can activate androgen regulated gene 
transcription, and PSA (kallikrein-like serine protease) expression is elevated 
even in the absence of androgens. This mechanism is supported by data 
showing that interleukin-6 can activate the AR in a ligand-independent 
manner. However, the oncogenic role of STAT3 in prostate cancer is not 
clearly established and STAT3 has also been correlated with interleukin-6-
induced growth arrest in cell lines, including LNCaP cells (Edwards J., 
2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6: How the JAK/STAT 
pathways affects prostate cancer 
growth (Edwards J., 2005). 
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2. AIM OF RESEARCH 
 
 	  
STAT3 plays a central role in a range of physiologic process, and 
when subverted in cancer, can be a central mediator of malignant cellular 
function. The high incidence of STAT3 activation in human tumor cells of 
diverse origins (Migone et al., 1995; Gouilleux-Gruart et al., 1996; Weber-
Nordt et al., 1996; Garcia et al., 1997; Takemoto et al., 1997) suggest an 
important role for aberrant activation of STAT3 signaling in regulanting 
fundamental cellular processes associated with malignant transformation. 
Consistent with an indispensabile function during devlopment (Takeda et al., 
1997), STAT3 signaling has been implicated in regulation of apoptosis, 
differentiation, and cell proliferation (Fukada et al., 1996; Ihara et al., 1997; 
Bromberg et al., 1998; Turkson et al., 1998). We predicted that this persistent 
STAT3 signaling affects a wide range of cellular function, many of which 
still remain to be characterized such as the mitotic process. Literature 
screening data indicating that TPX2 protein has multiple function during 
mitosis, including microtubule nucleation around the chromosomes and the 
targeting of Xklp2 and Aurora A to the spindle; TPX2 is also overexpressed 
in many tumor types. Then the present research has intended to investigate, 
through in vitro and in vivo methods, the role of STAT3 as transcription 
factor in the regulatory region of TPX2 gene coding for a protein involved in 
the complex process of mitosis, and identified as one of the microtubule-
associated proteins. Potential STAT3-binding sites obtained by consulting 
databases as MatInspector and ElDorado have been tested by EMSA and 
Chomatin-Immunoprecipitation experiments. To confirm our results in vivo 
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reporter gene assay has been conducted in M14 cells treated with specific 
phosphopeptidic inhibitor of STAT3 (Turkson et al., 2001). 
In variety of human tumor STAT3 has been descrive as molecular hub 
to link extracellular signals to transcriptional control (Brantley E. and 
Benveniste E.N., 2008). Whereas STAT3 is tyrosine phosphorylated by three 
types of kinases and regulated broad programs of gene expression, it uses a 
precise sequence of functional actions by multiple coactivator complexes and 
post-translational modifications for mediating gene activation. This 
observation suggests that STAT3 may act upstream of several transcription 
programs such that different targets may be activated or repressed at distinct 
time point following STAT3 activation. A dynamic interplay between 
coactivator/corepressor complexes as “sensors” to integrate signaling inputs 
to generate precise programs of gene expression (Rosenfeld M.G., 2006) was 
investigated in several tumor cell lines, particularly in melanoma cell lines 
M14 stimulated with EGF and IL-6 to simulate different pathways of STAT3 
activation. The cells have been subjected to co-immunoprecipitation and 
chromatin-immunopurification to study STAT3-interacting proteins and to 
demonstrate the requirement of specific coactivators in transcriptional 
activation of STAT3-regulated genes.  
Furthermore, activated STAT3 has been implicated as an important 
signaling molecule for IL-6 to activate AR (androgen receptor) in androgen-
dependent and –independent cell lines (Edwards J., 2005; Kaarbø M. 2007). 
The aim of last part of this study was to explore the relation between the 
immunochemical expression of  p-Tyr705 STAT3 and its post-traslational 
modificazions (PTMs), as acetylation and glutathionylation, in normal and 
malignant human prostate tissues (FFPE) and clinicopathological features. 
Parallel to investigate how differences in PTMs of STAT3 can influence gene 
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expression and interactions with coactivators, immunoblottig analysis, Co-IP 
and ChIP experiments have been conducted in LNCaP and PC3 cells treated 
with IL-6 and H2O2, to simulate a physiological response to citokines or to 
oxidative stress. 
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3. MATERIALS AND METHODS 
  
3.1 Cell lines and cell culture 
 
Human cervical adenocarcinoma cells (HeLa) were grown in 
Dulbecco’s minimal essential medium (DMEM). Human melanoma cells 
(M14) and human prostate cancer cells (LNCaP and PC3) were maintained in 
RPMI-1640 (Roswell Park Memorial Institute) medium, supplemented with 
10% v/v fetal bovine serum (FBS), 100 units/ mL penicillin and 100 µg/mL 
streptomycin (Invitrogen, Burlington, ON, Canada), 1% w/v sodium 
pyruvate, 2mM glutamine. All cells were grown to 70-80% confluence at 
37°C with 5% CO2. 
 
 
3.2 Cells treatment with IL-6, EGF, H2O2 
  
 All cell lines were grown in 25 cm2 flasks for cell fractionation and 
treated with IL-6 at final concentration of 50ng/ml, EGF (Epidermal growth 
factor, Sigma Aldrich) 100 ng/ml, H2O2 1mM for 5, 15, 30, 60, 90, 120, 240 
minutes. For the inhibitions, cells were treated with anacardic acid 100µM 
for 40 minutes at 37°C and 3-ABA (3-aminobenzamide) at final 
concentration of 3 mM for 24h. 
 
 
3.3 Cell fractionation 
 
Cells, treated and untreated, were washed with serum-free medium 
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and scraped with cold PSB. Cells were harvested by centrifugation and 
washed twice with PBS. Cells were than lysed by pi petting in hypotonic 
ELB buffer (10mM Hepes pH 8, 10 mM NaCl, 3 mM MgCl2, 1mM DTT or 
orthovanadate) supplemented with proteases inhibitors. The homogenate was 
cwntrifuged at 600 g for 3 minutes at 4°C and the supernatant was again 
centrifuged at 15,000 g for 15 minutes at 4°C to abtain the clarified 
cytoplasm. The crude nuclear franction obtained in low-speed centrifugation 
(pellet) was further purified by resuspending the homogenate with a 
hypodermic needle in lysis buffer ( 10 mM Hepes pH 8, 10mM KCl, 1,5 mM 
MgCl2, 30 mM sucrose, 0,5 mM DTT or 1 mM orthovanadate and proteases 
inhibitors) containing 0,05% v/v Triton X-100, incubating for 10 min in ice. 
The suspention was centrifuged at 14000 g for 10 min at 4°C and the nuclear 
pellet was washed with lysis buffer containing 1 mM CaCl2. The purified 
nuclei, after quantification performer by measuring spectrophotometrically 
the absorbance at 260 nm, were resuspended in 1X Laemmli Buffer ( 2% 
SDS, 62,5 mM Tris-HCl pH 6.8, 10% v/v glycerol, 5 mM DTT, 0.02% 
bromophenol blue) and sonicated with Labsonic M ( Sartorius) ( 3 x 30 
seconds strokes) or further manipulated to obtain the nuclear extracts. 
 
 
3.4 Nuclear extracts preparation 
 
Nuclear extracts were obtained by resuspending the purified nuclei in 
a hypertonic buffer ( 20 mM Hepes ph 8, 20% v/v glycerol, 0.4 M KCl, 1 
mM EDTA, 1mM DTT), supplemented with proteases inhibitors, all in 1:100 
diluition. After a 30 minutes incubation in ice with the buffer, the suspention 
was centrifuged at 14000 rpm for 30 minutes at 4°C. The supernatant 
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containing the nuclear extracts was collected, while the pellet was again 
resuspended in the hypertonic buffer and incubated in ice for 15 minutes 
twice. The suspention was then centrifuged at 14000 rpm for 10 minutes at 
4°C and the second and the third supernatant, containing the nuclear extracts, 
were added to the first one. 
 
 
3.5 Western blotting 
 
Samples in 1X Laemmli buffer were boiled for 3 minutes and than 
loaded on 7.5% or 10% SDS-acylamide gel. After electrophoresis, proteins 
were electrotransferred to polyvinylidene difluoride (PVDF, Immobilon, 
Millipore) membranes using a semi-dry blotting apparatus (Pharmacia) in 10 
mM CAPS ph 11, containing 20% v/v methanol. Membranes were 
extensively blocked with TBST (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 
0.1% v/v Tween 20) containing 0.2% w/v I-Block (Tropix) for colorimetric 
detection. Membranes were incubated with the primary antibodies, 
apprpriately diluited, for 1 hour or overnight at 4°C, washed and incubated 
with anti-mouse or anti-rabbit IgG conjugated with alkaline phosphatase or 
horseradish peroxidase (Jackson Immunoresearch) for 1 hour. After washing 
in TBST, membranes were subjected to colorimetric detection using alkaline 
phosphatase substrates (Roche). Alternatively, after electrophoresis the gels 
were stained with Coomassie R-250 or Bio-Safe colloidal coomassie 
(BioRad) to visualize total protein. 
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3.6 Chromatin-Immunoprecipitation (ChIP) 
 
3.6.1 ChIP for TPX2 experiment 
A chromatin immunoprecipitation experiment was carried out on M14 
cells (Chichiarelli et al., 2002). DNA- proteins cross-linkages were formed 
by treating intact cells with cis-diamminedichloroplatinum. This cross-
linking reagent was chosen for its high efficiency and for its capacity to 
identify the protein directly interacting (Lemaire et al., 1991). DNA-protein 
cross-linked complexes were purified  by gel filtration and subjected to 
immunoprecipitation with a polyclonal anti-Stat3 antibody (Santa Cruz 
Biotechnologies, Santa Cruz, CA, USA). The DNA was purified and 
enriched, by PCR, with the same 150-base pairs fragment used for the 
experiment in vitro: 
5’-CTAAAAAATTAGCTGGGCGTC-3’ (forward) 
biotin-5’-GACAAAATTTCGCTCTTTCAC-3 (reverse) 
  
3.6.2 ChIP for Results 4.2 and 4.3 
DNA-protein cross-linked complexes were formed in cell lines using 
of 1% formaldehyde (5 min at 37°C) that has propensity to form protein-
protein cross-linkages. The immunoprecipitation procedure was carried out 
by anti-STAT3 antibody immobilized on IgG rabbit magnetic beads 
(Dynabeads, Invitrogen). The DNA was then purified by phenol-chloroform 
extraction and ethanol precipitation, and amplified with the primers listed in 
Table 1. The amount of immunoprecipitated DNA subjected to amplification 
was measured by means of a QUBITTM Fluorometer (Invitrogen) following 
the manufacturer’s instructions. 
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TABLE 1. Promoter-specific primer sequences used for ChIP assays 
Gene             Promoter-specific primers 
 
 
DNMT1 
 
 
c-Myc 
 
 
P21 
 
 
CDC25A 
 
 
KLK3I 
 
 
SRD5A2 
 
 
EME-1 
 
 
CRP 
 
 
Α2-Macroglobuline 
 
 
MMP-2 
 
 
MMP-9 
 
 
Survivine 
 
 
hTERT 
 
5’-CAAAGTGCTGGGATG-3’ (forward) 
5’-CATGCCACTTCTATAC-3’ (reverse) 
 
5’-CTCCTGCCTCGAGAAG-3’ (forward) 
5’-CTTTTATACTCAGCGCGATC-3’ (reverse) 
 
5’-GATCAGGTTGCCCTTTTTTG-3’ (forward) 
5’-GAAATTGAGGTCCACTGAAC-3’ (reverse) 
 
5’-GTTTGGCGCCAACTAGGA-3’ (forward) 
5’-GAAAACCAAGCCGACCTAC-3’ (reverse) 
 
5’-GATCCATGAGGTTCTCAC-3’ (forward) 
5’-GAGTGGAAGGATATACTTAG-3’ (reverse) 
 
5’-CAAGATGGAGTCGCTCTG-3’ (forward) 
5’-GTAAGCCTTAACTTGGCCTC-3’ (reverse) 
 
5’-CAAGCTCTGTGGATGGTAAC-3’ (forward) 
5’-CTCTCCTCAGGGCTATTAC-3’ (reverse) 
 
5’-CATCTTAGTCTAATAGGACTG-3’ (forward) 
5’-CTAGTGTCTGTATCGTAATATAG-3’ (reverse) 
 
5’-GCTTATTAGCTGCTGTAC-3’ (forward) 
5’-GTCAAGGTTAATTCCTGG-3’ (reverse) 
 
5’-GAAGTCAGGGTAGTGGTG-3’ (forward) 
5’-GATTATCAGCATATCAGGATCTG-3’ (reverse) 
 
5’-GTATCCTTGACCTTCTTTC-3’ (forward) 
5’-GTGGTGATTGGTTTTAATTAG-3’ (reverse) 
 
5’-GTTGCAGTGAGCTGAGATC-3’ (forward) 
5’-GTGCCTCCACTGTCTTTTTC-3’ (reverse) 
 
5’-CTTTGCAGGTGTGATCTC-3’ (forward) 
5’-CTTTTCAGCCTCAGACTG-3’ (reverse) 
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3.7 Total RNA extraction 
 
Cells were harvested and total RNA was isolated with TRIzol® 
Reagent (Invitrogen) following the manufacturer’s instructions. RNA was 
precipitated by adding isopropanol and subsequently centrifuged at 12,500 g 
for 10 minutes at 4°C. The precipitated RNA was washed with 75% ethanol 
and air dried. Total RNA was than resuspended in RNase-free water and 
subjected to reverse transcription. 
 
 
3.8 cDNA synthesis and quantitative Reverse Transcription-PCR 
 
The reverse transcription of RNA was conducted with cDNA 
Synthesis Kit (Bioline), according to the manufacturer’s instructions. The 
reaction mixture was prepared incubating total RNA with oligo dTs at 65°C 
for 10 minutes, then the primed RNA was incubated with the reverse 
transcriptase at 42°C for 1 hour. The reaction was terminated by incubating at 
70°C for 15 minutes. Gene expression was evaluated with specific primers 
(Quanti-Tect QIAGEN) by Real-Time PCR using a MJ MiniOpticon 
Detection System (BioRad Laboratories) with SYBR green fluorophore using 
Brilliant SYBR Green QPCR Master Mix (Stratagene). All reactions were 
carried out at least in duplicate. GAPDH (QuantiTect QIAGEN) gene was 
used as reference for normalization  and the relative quantification was 
analyzed using Gene Expression analysis for iCycler iQ real-time PCR 
detection 
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3.9 Electophoresis Mobilty Shift Assay (EMSA) 
 
An EMSA experiment was performed using, as probes, the 33P-end 
labeled double-stranded oligonucleotides corresponding to the four potential 
Stat3-binding sites present in the region between the BCL2L1 and the TPX2 
genes. The probes were treated with the nuclear extracts prepared from M14 
cells. Protein-DNA complexes were resolved by non-denaturing 5% 
polyacrylamide gel electrophoresis and specific Stat3/DNA complexes were 
detected by autoradiography. Poly (dI-dC).poly (dI-dC) was present as a 
competitor in a 500-, 1000- or 2000-fold excess. 
Effect of mutation of the Stat3 consensus sequence. The gel-retardation was 
performed with a similar DNA fragment, mutated within the Stat3 consensus 
sequence #3 (TGCAGGAGAATCACTTCCATGTTGGGGGAG GTTCA, 
the mutated bases are indicated in bold characters).  
 
3.9.1 EMSA analysis with radiolabeled probe #3 
Nuclear  extracts from M14 and ARO cells were preincubated for 30 
min with or without 1 mM phosphopeptide PpYLKTK-mts (Tukson et al., 
2001; Rojas et al., 1998) before the addition to the probe. The probe was 
tested with the nuclear extracts prepared  from M14  cells treated or untreated 
with the inhibitor peptide. M14 cells were grown in plastic dish in RPMI 
supplemented with 10% calf serum and were incubated for 48 hours with or 
without 1mM phosphopeptide inhibitor. 
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3.10 In vitro DNA-affinity 
 
A biotinylated DNA fragments from the 5’-flanking region (-4379/-
4229) of the human TPX2 gene was prepared by PCR using the following 
primers: 5’-CTAAAAAATTAGCTGGGCGTC-3’ and biotin-5’-
GACAAAATTTCGCTCTTTCAC-3’. The other biotinylated 
oligonucleotides of 100 bp, homologous to the promotes of the genes that 
spanning STAT3 sites, were prepared by PCR using the primers listed in the 
table above. These probes were immobilized on magnetic Dynabeads (Dynal, 
InVitrogen, Carlsbad, CA, USA) M-280-Streptavidin (200 pmol/mg beads) 
and incubated with nuclear extracts of M14, PC3 and LNCaP cell in the 
presence of a 1000-fold excess poly(dI-dC).poly(dI-dC). The specifically 
bound proteins were eluted with Laemmli buffer and analyzed by SDS-gel 
electrophoresis in 10% polyacrylamide and Western blotting using specific 
antibodies (Cell Signaling Technology, Beverly, MA, USA). A control 
experiment was carried out by using streptavidin beads saturated with biotin.  
 
 
3.11 Reporter plasmid and luciferase assay 
 
The reporter gene constructs bearing the fragment of the human   5’-
flanking region (-4379/-4229) of the human TPX2 gene were generated by 
PCR amplification of human genomic DNA. The primers for the PCR 
reaction were as follows:  
tpx2-rgsacI 5’-GGGAGCTCGTCTGTCTTTTTAC -3’ (forward)  
tpx2-rgbglII 5’-GGGAGATCTGAAATTTGTAAGGTAAC-3’ (reverse). 
The  bp of the 5’-flanking fragment were then cloned into the SacI/BglII site 
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of firefly luciferase pGL3-promoter vector (Promega) and verified by 
sequencing. For luciferase assays, cells (5 x 104 cells/well) grown in a 
standard culture medium containing FBS in 24-well plates were transiently 
transfected with the reporter plasmids using TurboFectTM in vitro 
Transfection Reagent (Fermentas) according to the manufacturer’s 
instructions. After treatment, cells were lysed, and luciferase activities were 
determined by a chemiluminescence assay using the luciferase assay kit 
(Promega) and a Appliskan luminometer. 
 
 
3.12 TISSUE SPECIMENS 
 
3.12.1 Immunohistochemical Stained 
 
Briefly, formalin fixed, paraffin embedded tumor and normal sections 
(5 µm) were deparaffinized in xylene and rehydrated through graded 
ethanols. The slides were placed in citrate buffer (10 mM., pH 6.0) and 
microwaved for 60 minutes for antigen retrieval. Endogenous peroxidase 
activity was quenched with 0.3% hydrogen peroxide for 30 minutes. The 
sections were incubated overnight at 4°C with rabbit polyclonal anti-p-
STAT3 at Tyr 705 (p-STAT3) antibody or rabbit polyclonal anti-total 
STAT3 antibody (Cell Signaling Technology). The secondary antibody is 
with FITC goat-anti-Rabbit-IgG (Jackson Immunoresearch). The two 
antibodies were used at a dilution of 1:25. The sections also were 
counterstained with DAPI in PBS (0,03µg/ml) and mounted with glass 
coverslips. Formalin fixed, paraffin embedded sections of prostate cancer 
specimens served as a positive control in each experiment. For the negative 
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control the primary antibody was omitted during the procedure (Horiguchi A. 
et all, 2002). 
 
 
3.12.2 Protein Extraction From FFPE (Formalin-Fixed Paraffin 
Embedded) 
 
Before protein extraction, 5 µm tissue section were weighed (about 3 
approximately equals 30 mg) (Ilona Gräntzdörffer, 2010). The 
deparaffinization was carried out incubating twice with xylene for 5 minutes 
at room temperature before rehydration in a graded series of ethanol (100%, 
90% and 70%) for 10 min each. The eppendorf were put in vacuum dryer for 
15’. Afterwards, the samples were mixed with FFPE extraction buffer (150 µl 
per sample), sonicate for about 7-8 times, incubated at 100 °C for 20’ h and 
80°C for 2 hours, than centrifuged for 30 min at 14.000 rpm. The supernatant 
was supplemented with 1/10 volume of Thiourea 1M and stored at −20 °C. 
The protein extraction of the FFPE tissue slides was similar. Protein 
concentrations were determined by the BCA assay (Bio-Rad, Munich, 
Germany). 
 
 
3.12.3 Extraction of total RNA from formalin-fixed paraffin-embedded 
tissue 
 
Total RNA was extracted from three 10 µm thick FFPE sections 
(corresponding about 30 mg of tissue). RNA was purified with 
WAXFREETM paraffin kit (TrimGen) according to the manufacturer’s 
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instructions. RNA was quantified spectrophotometrically, and its quality was 
ossesse by 1.5% agarose gel electrophoresis and staining with ethidium 
bromide. To rule out the possibilità of DNA contamination, the resolved 
RNA was incubated with 10 µm/ml RNase-free DNase at 37°C for 30 min. 
 
 
3.12.4 Reverse Transcription and RT2-PCR 
 
The reverse transcription was carried out with PrimeScriptTM RT 
reagent Kit (Takara). Gene expression was evaluated with specific primers 
(Quanti-Tect QIAGEN) by Real-Time PCR using a MJ MiniOpticon 
Detection System (BioRad Laboratories) with SYBR green fluorophore using 
Brilliant SYBR Green QPCR Master Mix (Stratagene). 
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4. RESULTS 
 
 
4.1 IDENTIFICATION OF A NOVEL STAT3 TARGET GENE. 
 
 
An inspection of the 5’-region of human TPX2 gene on chromosome 
20 revealed the presence of many consensus sequences for transcription 
factors, among which are some putative sites for STAT factors. Among 
the genes whose expression is favoured by STAT3 and which may 
contribute to the oncogenic potential of STAT3 are those coding for the 
anti-apoptotic proteins Bcl-2, Mcl-1, survivin, and Bcl-xL. However, the 
binding sites of STAT3 on the promoters of these genes have not always 
been experimentally demonstrated. In particular, the 5'-flanking region of 
the human BCL2L1 gene, coding for Bcl-xL, has many potentially binding 
sites for STAT proteins, but none of these correspond closely to the 
consensus sequence of Stat3. An inspection of this region on human 
chromosome 20 has revealed that the gene for TPX2 is in proximity with 
that for Bcl-xL, the two genes being transcribed in opposite direction on 
DNA, so that they have in common a 5'-flanking region of more than 
16,000 base pairs (Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 7: Sequences and positions of putative Stat3-binding elements on the 5'-flanking region of the TPX2 gene. 
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In order to identify high-affinity binding sites for Stat3 possibly present in 
this region, we carried out an EMSA experiment with nuclear extracts from 
M14 melanoma cells, where Stat3 has already been shown to be 
constitutively activated (Eufemi et al., 2004). Protein-DNA complexes were 
resolved by non-denaturing 5% polyacrylamide gel electrophoresis and 
specific Stat3/DNA complexes were detected by autoradiography. Only one, 
the probe #3, of the four potential binding sites examined, showed in Figure 
1A, appeared to bind Stat3 with high affinity, since the binding was not 
affected by the presence of a 1000-fold excess of competitor Poly (dI-
dC).poly (dI-dC) (Figure 8A).  
 
 
 
 
 
 
 
 
Fig. 8: A) Stat3 DNA-binding activity as measured by EMSA in nuclear extracts prepared from M14 cells treated 
with poly(dI-dC).poly (dI-dC) as a competitor in a 500-, 1000- or 2000-fold excess in lanes 1, 2 and 3 respectively. 
B) Effect of mutation of the Stat3 consensus sequence. An EMSA experiment with a mutated probe #3. Lane 1: 
probe #3. Lane 2: mutated probe #3. 
 
This site is located at -4305/-4297 base pairs from the transcription start of 
TPX2 and has a TTCCCGGAA sequence, which is identical to the sequence 
bound by activated Stat3 in the promoter of gene CDKN1A, coding for the 
protein p21WAF1/CIP1. Instead no complex was formed when the gel-
retardation was performed with a mutated probe #3 
TGCAGGAGAATCACTTCCATGTTGGGGGAGGTTCA (with, the 
mutated bases are in indicated in bold characters). (Figure 8B) 
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Since other members of the Stat family might have been responsible for the 
formation of this DNA-protein, a 150-base pairs DNA fragment (-4379 to -
4229 in the 5’-flanking region of the TPX2 gene, containing the same 
consensus sequence, was immobilized on magnetic beads and tested for the 
binding of proteins from the M14-nuclear extract in the presence of a 1000-
fold excess of aspecific DNA. The proteins that were specifically bound were 
eluted and analyzed by gel electrophoresis and Western blotting, and Stat3 
was clearly identified among them, as shown in Figure 9.  
 	   
 
 
 
These results demonstrate that the examined region in the 5’-flanking 
sequence of TPX2 gene is able to bind Stat3 in vitro with high affinity. To 
detect the binding of Stat3 in vivo to the same sequence, a ChIP experiment 
was carried out on M14 cells. The DNA-Stat3 complexes were 
immunoprecipitated with an anti-Stat3 antibody and the DNA was purified 
and analyzed by PCR. As shown in Figure 9, the immunoprecipitated DNA 
was enriched with the same 150-base pairs fragment used for the experiment 
in vitro, containing the consensus sequence for Stat3 as described before. 
 
 
 
 
 
 
 
 
 
 
Fig. 10: In vivo binding of Stat3 to the DNA fragment #3. 
 
Fig. 9: In vitro binding of Stat3 to the DNA 
fragment #3. Lane 1, nuclear proteins eluted from 
the oligonucleotide. Lane 2, nuclear proteins 
obtained from control. 
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Thus, constitutively activated Stat3 is bound in vivo to this site found in the 
5'-region of the TPX2 gene. This finding supported the possibility that Stat3 
is involved in the regulation of TPX2 expression. To verify this hypothesis, 
the effect of a specific inhibitor of Stat3 on gene expression was tested. 
Tukson et al. (2001) have shown that a phosphopeptide able to interact with 
the SH2 site of STAT3 inhibits the binding of STAT3 to DNA in vitro and in 
vivo, probably by disrupting the active STAT3 dimers. When used in vivo, it 
might also associate with non-phosphorylated cytoplasmic STAT3 monomers 
and form STAT3-peptide complexes that would be incapable of binding to 
the docking sites of receptors for subsequent de novo phosphorylation and 
activation. By adding a membrane translocating sequence (Rojas et al., 1998) 
the peptide acquires a full cell-membrane permeability. In the first place this 
peptide was tested for its inhibitory activity on the formation of the STAT3-
DNA complex as detected by gel retardation using the nuclear extracts of 
M14 cells and the previously described consensus sequence. As expected, the 
presence of the peptide in the nuclear extracts abolished the formation of the 
complex (Figure 11).  
 
 
 
 	   	   
 
 
 
 
Next, the M14 cells in culture were treated with the peptide and then assayed 
for the presence of TPX2 by gel electrophoresis and Western blotting. Figure 
Fig. 11: EMSA analysis with 
radiolabeled probe #3 to verify the 
effects of Stat3 inhibition by the 
phosphopeptide PpYLKTK-mts in M14 
cells. 
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12 shows that treatment with the inhibitory peptide decreased significantly 
the amount of TPX2, while leaving essentially unaltered the total proteins of 
whole nuclear extracts as evidenced by Coomassie staining. 
 
 A  B 
 
 
 
 
 
 
 
 
 
 
 
Furthermore, the nuclear extracts of the cells treated with the peptide lost 
their capacity to form the protein-DNA complex with the consensus sequence 
for STAT3 (Figure 13). The effect of  the peptide on the transcription of the 
TPX2 gene was analyzed by RNA isolation, reverse transcription and 
amplification. As shown in Figure 13, TPX2 expression was strongly 
decreased by the action of the inhibitory peptide in comparison to the 
untreated cells, as showed in RT-PCR assay for TPX2 expression.  
 
 
 
 
 
 
 
 
 
Fig. 13: RT-PCR for TPX2 expression in M14 cells treated and non with inhibitory phosphopeptide 
 
To demonstrate that Stat3 activation regulated in vivo TPX2 expression, M14 
cells were transiently transfected with a luciferase reporter construct 
containing the -4379 to -4229  region containing the putative Stat3 binding 
Fig. 12: A) Western Blotting analysis of TPX2 after treatment of M14 
cells with 1mM phosphopeptide inhibitor for 30 minutes, compared to 
untreated cells. B) Coomassie staining of the same amount of protein 
showed in A).  	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site for reporter activity assay, in the presence or in the absence 
phosphopeptide inhibitor. Whereas in untreated condition M14 cells showed 
an increase of luciferase expression eightfold around basal levels, this effect 
was repressed in M14 treated with STAT3 inhibitor (Figure 14). This result 
suggests that STAT3 is recruited on the TPX2 gene promoter and is involved 
in its activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14: M14 cells, treated and not with inhibitor phosphopeptide, were transfected with a vector expressing a 
luciferase reporter gene containing a STAT3 consensus binding site for TPX2 gene. As a control, the same 
experiments were performed in parallel using a pGL3-control plasmid. 
 
 
This results and the effect of the same peptide were confirmed on another cell 
line, the ARO cells, which are human anaplastic thyroid cancer cells with 
constitutively activated Stat3. As a whole, these results indicate that STAT3 
contributes to the activation of TPX2 expression. 
 
 
 
 
	   pGL3-­‐Ctr	   pGL3-­‐tpx2	   pGL3-­‐Ctr	   pGL3-­‐tpx2	  
Inhibitor	  
phosphopeptide	   -­‐	   -­‐	   	   +	   +	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4.2 STUDY ON DYNAMIC INTERPLAY OF STAT3-ASSOCIATED 
PROTEINS IN RESPONSE TO MULTIPLE ACTIVATION 
PATHWAYS. 
 
 STAT3 has been shown to be constitutively activated in many 
melanoma cell lines. However, the characterization of the STAT3-containing 
complexes in these cell lines is still lacking. We proceeded therefore to 
characterize such complexes in the well characterized M14 melanoma cell 
line. The activation of STAT3 may occur in through different parhways, we 
hypotized an interplay between PARP-1 STAT3-associated proteins and 
CBP/P300, a protein with histone acetyl transferase activity and 
transcriptional coactivator of STAT3, in response to different stimulations. 
 The specific binding in vitro of nuclear proteins to a DNA 
fragment containing a known STAT3 consensus sequence was analyzed by 
incubating the nuclear extracts of M14 cells stimulated with IL6 (100ng/ml) 
for 5 min, EGF (100ng/ml) for 10 min and non stimulated with a double 
stranded fragment of DNA, present in the 5'-regulatory region of the CDKN1A 
gene, which codes for the protein p21WAF1/CIP1. This is a 100 base-pair 
sequence, containing the STAT3-consensus TTCCGGGAA. The DNA 
fragment, biotinylated at its 5'-end, was immobilized on streptavidin-Dynal-
magnetic beads and incubated with the nuclear extract in the presence of a 
500-fold excess of unspecific competitor DNA. The specifically bound 
proteins were then eluted in high salt and analyzed by  SDS-PAGE. This was 
followed either by Coomassie staining or by Western blotting. The Coomassie 
staining revealed the presence of many protein bands, one of which in the 
110-kDa region did not correspond to any other known STAT3-interacting 
protein. This band was eluted, and its tryptic hydrolyzate examined by mass-
spectroscopy, which allowed to identify it as PARP-1 (Figure 15). When the 
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specifically bound proteins were analyzed by Western blotting, STAT3 was 
found to be present, as expected, and also PARP1 (Figure 17).  
 
 
 
 
This confirmed the identification provided by the mass-spectroscopy analysis 
and also the in vitro affinity of PARP1 to the STAT3-containing 
enhanceosome of   the CDKN1A gene. The binding of PARP-1 to this 
particular DNA region was tested also by the use of nuclear extracts from 
HepG2 hepatoma cells, where STAT3 is normally non-activated unless they 
are subjected to the stimulatory action of a cytokine or a growth factor. In 
these cell lines we found a different composition of STAT3-dependent 
enhanceosome of the CDKN1A gene. Our attention was then been focused on 
protein P300 (Figure 16). 
 
 
 
 
 
NAME 
 
SWISS PRONT 
ACCESSION 
MW 
kDa 
54 kDa nuclear RNA and DNA binding protein Q 15233 54 
Poly ADP-Ribose Polymerase-1 P 09874 113 
APEX-1 P 27695 116 
Ku 80 P 13010 80 
ERp57 P 30101 57 
Splicing Factor, Proline and Glutamine Rich P 23246 76 
Mitf O 75030 55-58 
Rb  P 06400 105 
NOME 
 
SWISS PRONT 
ACCESSION 
MW 
kDa 
54 kDa nuclear RNA and DNA binding protein Q 15233 54 
P300 Q 92831 300 
Brg-1 P 51532 45 
Scr-1 P A4H5H2 75 
Splicing Factor, Proline and Glutamine Rich P 23246 76 
Mitf O 75030 55-58 
Rb P 06400 105 
Fig. 15: STAT3-interacting 
proteins in 5'-regulatory 
region of the CDKN1A gene 
obtained by mass-
spectroscopy analysis from 
M14 stimulated and non 
with EGF. Same results has 
been found in A431 cells. 	  
Fig. 16: STAT3-
interacting proteins in 
5'-regulatory region of 
the CDKN1A gene 
obtained by mass-
spectroscopy  analysis 
from M14 stimulated 
with IL6. Same results 
has been found in 
HepG2 and HeLa cells. 	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In order to verify if such PARP-1-STAT3 and P300-STAT3 associations take 
place also in the regulatory regions of other genes, we exploited the same 
procedure described above to analyze the interactions of nuclear extracts from 
M14 and HepG2 cells stimulated with IL6 with two other DNA fragments 
containing well characterized STAT3-consensus sequences, i.e. those of the 
α2-macroglobulin gene and the MMP9 gene. PARP-1 was found to be present 
among the proteins specifically bound to DNA in M14 cells, but not in HepG2 
cells treated with citokynes, where instead the P300 protein was observed 
(Figures 18, 19).  
   
A      B 
 
 
 
 
 
Fig. 18: Western blotting (A) Ab P300 and (B) Ab PARP-1 of total nuclear extracts and proteins specifically bound 
to of the p21, α2-macroglobulin and the MMP2 genes in M14 cells. 
 
Fig. 17: Western 
blotting of STAT3-
interacting proteins on 
regulatory region of 
CDKN1A in M14 cells 
stimulated with IL6 
and EGF. 
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 A     B 
 
  
 
 
 
 
Fig. 19: Fig. : Western blotting (A) Ab P300 and (B) Ab PARP-1 of total nuclear extracts and proteins specifically 
bound to of the p21, α2-macroglobulin and the MMP2 genes in HepG2 cells stimulated with IL6. 
 
It is evident that the presence of proteins, PARP-1 or CBP/p300, as 
components of nucleoproteins complexes depends on specific pathways of 
STAT3 activation. Our attention was focused in melanoma cell (M14), 
cellular model of choice, because STAT3 is constitutively activated by src but 
is also responsive to stimulation by cytokine (IL-6 100ng/ml), and growth 
factors (EGF100ng/ml). To test whether the interactions between PARP-1 or 
CBP/p300 and DNA-bound STAT3 is present also in vivo, were performed 
ChIP and CoIP experiments. The nuclear extracts from M14 cells stimulated 
with EGF and IL6 were treated with formaldehyde, the immunoprecipitation 
with Ab STAT3 was carried out as described in Materials and Methods. An 
analysis of the immunopurified material by Western blotting revealed the 
presence of PARP-1 when STAT3 was activated by SCR/EGF. (Figure 20) 
On the other hand, treatment with anti-PARP-1 antibodies revealed the 
presence of STAT3 in the immunopurified fraction (data not shown). After 
treatment of  IL6, we found the presence of CBP/P300 instead of PARP-
1.This result shows that the two proteins are associated even in the absence of 
DNA, either through a direct association or through an interaction mediated 
by another protein.  
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The same experiments performed after pretreatment of the cell with specific 
inhibitors: 3-ABA for PARP-1 and anacardic acid for CBP/p300, showed that 
interactions STAT3-PARP-1 and STAT3-CBP/p300 were abolished (Figure 
21). 
 
 
 
 
 
 
 
 
 
Fig. 21: Anti-STAT3 immunoprecipitates from M14 cells stimulated with EGF and Il6 and treated with anacardic 
acid, as P300 inhibitor, and 3-ABA, as PARP-1 inhibitor, analyzed by Western blot with antibodies raised against 
P300 (top panel) and PARP-1 (bottom panel). Immunoprecipitation in the last lanes refer to rabbit IgG shows no 
signal indicating assay specificity.  
 
 
 
To test whether the interaction between PARP-1, P300 and the DNA-bound 
STAT3 is present also in vivo, chromatin immunoprecipitation experiments 
were performed. Intact M14 cells were stimulated with EGF or IL6 and after 
treated with the specific inhibitors, 3-ABA in cells with EGF, anacardic acid 
Fig. 20: Anti-STAT3 immunoprecipitates 
from M14 cells untreated and stimulated 
with EGF and Il6 analyzed by Western 
blot with antibodies raised against PARP-1 
(top panel) and P300 (bottom panel). 
Immunoprecipitation in the last lanes refer 
to rabbit IgG shows no signal indicating 
assay specificity.  	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in cells with IL6. The cross-linking was carried out with formaldehyde, and 
immunoprecipitated with antibody against STAT3.  The immunoprecipitated 
DNA was analyzed for enrichment of the CDKN1A (P21), the α2-
macroglobulin and the MMP9 enhancers by PCR amplification with specific 
primers. As shown in Fig. 22, cross-linking with formaldehyde led to the 
enrichment of the three enhancers sequences in the immunoprecipitated DNA 
in both conditions of stimulation. After the treatment with specific PARP-1 
and P300 inhibitor we observed a down-regulation of same genes.  
 
 
A B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 22: PCR analysis of the enrichment of STAT3-binding sites in the immunoprecipitated DNA of p21, mmp2 and 
α2macroglobulin genes in M14 cells. (A) Cells were stimulated with EGF and after treated with 3-ABA (top panel) 
or not (bottom panel). (B) Cells were stimulated with IL6 and after treated with Anacardic acid (top panel) or not 
(bottom panel). Gapdh gene was used as reference gene.  
 
 
 
To study the functional effects of the interaction between PARP-1/STAT3 and 
P300/STAT3 we performed experiments of RT-PCR in the same conditions 
descrive above. Figure 23  shows that in both cases the transcription of the 
three genes was significantly repressed.  
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A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Fig. 23: Expression profile of p21, mmp-9, α2M, in M14 cells. (A) M14 treated with EGF and 3-ABA; (B) M14 
treated with IL6 and Anacardi acid. 
 
 
These results support the hypothesis that either PARP-1 or CBP/p300 appears 
to be specific co-activators of STAT3, in different pathways of activation, and 
their enzymatic activity seem necessary for this role. 
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4.3 STAT3 IN PROSTATE CANCER 
 
4.3.1 A) Studies on human prostate cancer: LNCaP hormone-responsive and PC3 
hormone refractory. 
 
4.3.1.1 Immunoblotting analysis of Stat3 protein and its Post-
Translational Modifications (PTMs). 
 
To study of involvement of STAT3 in prostate cancer we analyzed 
two well-characterized human cell lines, LNCaP and PC3. To simulate the 
different physiological conditions in which STAT3 is involved, cells were 
stimulated with IL-6 and hydrogen peroxide for 15 min. Nuclear extract were 
prepared and subjected to Western blotting to verify the presence of STAT3, 
phospho-Y705STAT3, acetyl-STAT3 and STAT3 glutathionylated (Figure 
24). In LNCaP untreated there was evidence of STAT3 and pY-STAT3 in all 
conditions, while the acetylation evidence after cytokines stimulation and the 
glutathionylation after oxidative stress. Surprisingly in untreated PC3 cell 
line we found STAT3 unphosphorylated and glutathionylated, instead the 
modification of STAT3 protein by acetylation was observed also after IL-6 
stimulation. 
 
 
 
 
 
  
 
 
Fig 24. LNCaP and PC3 cell lines were stimulated with IL6 (50ng/ml) and H2O2 (100mM) for 15 min at 37°C. 
Nuclear extracts from untreated and stimulated cells were analyzed by Western blot with antibody raised against 
STAT3, pY705-STAT3, acK685-STAT3. For the glutathionylation we performed a double staining with a monoclonal 
antibody against protein-bound GSH and Ab STAT3. 
 
Anti-STAT3 
 
 
Anti-pY705-STAT3 
 
 
Anti-acetyl-STAT3 
 
 
Anti-glutathionylated-STAT3 
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4.3.1.2 STAT3 nuclear protein interactors complex in PC3 cell 
line. 
 
To identify protein interactors of STAT3 in PC3 cell we performed 
coimmunoprecipitation assays using wild-type and stimulated cells with IL-6 
and H2O2. Anti-STAT3 antibodies conjugated beads were incubated with 
nuclear lysates of this cells and the immune complexes were fractionated on 
SDS-PAGE and proteins were detected by immunoblot. We focused attention 
on specific proteins previously described as coactivators of pY-Stat3 and U-
Stat3 (Chichiarelli S., 2010; Eufemi M., 2004; Grillo C. et al., 2006; Yang J., 
2007). Western blot analysis was performed with antibodies raised against 
p50 and p65 subunits of NFκB, p300, ERp57 and Ref1 (Figure 25). We 
observed that p50 and p65 subunits of NFκB were pulled down with STAT3 
in unstimulated conditions. Instead STAT3 coimmunoprecipitated with p300 
protein in IL-6 stimulated cells and with ERp57 and APE1/Ref-1 in response 
to H2O2 stimulation. We did not observe any complex formation using IgG as 
the immunoprecipitanting Ab, demonstrating assay specificity. AbSTAT3-
Ref-1 and STAT3-ERp57 complexes in IL-6 and H2O2 stimulated PC3 cells 
indicate that the interactions are primarily stimulus-dependent. 
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Fig. 25. Western blot of p50 and p65 
subunits of NFκB, p300, ERp57 and Ref-1 
in PC3 cells untreated and stimulated with 
IL6 and H2O2. Immunoprecipitation in the 
lanes control refer to rabbit IgG shows no 
signal indicating assay specificity. 
 
 
 
 
 
 
 
 
 
 
 
4.3.1.3 STAT3-DNA binding activity in the promoter of selected 
genes. 
 
Our next aim was to determine how the differences in post-
translational modifications and in cofactors could affect STAT3 protein in its 
function as transcription factors under physiological conditions.  Therefore 
chromatin immunoprecipitation (ChIP) experiments were carried out with the 
Ab STAT3 in LNCaP and PC3 cell lines untreated and stimulated as 
described before. Chromatin was prepared using formaldehyde cross-linking 
protocol, and occupancy of the promoters was analyzed by PCR using 
specific pairs of primers in the 5’-flanking regions of STAT3-binding 
sequences, representing the main functions under STAT3 control (see 
“Materials and Methods”). To ensure the specificity of the reaction, all 
immunoprecipitations were subjected to one round of preclearing with an 
excess of nonrelated IgG. Figure 26  shows that the fragments examinated 
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were enriched in the immunoprecipitated in different manner in both cell 
lines and in response to two stimulations.  
 
A LNCaP       PC3  B 
LNCaP  PC3 
 
 
 
 
 
 
 
Fig. 26: (A) PCR analysis of the enrichment of STAT3-binding sites in the immunoprecipitated DNA in comparison 
with the mock immunoprecipitation (performed with preimmune IgGs). The DNA fragments present in the 5’-
region of the genes indicated, and containing the STAT3 consensus sequence, were amplified with the primers 
shown in Table , as described in “Materials and Methods”. (B) Enrichment of STAT3-binding site of α2-
Macroglobulin, c-MYC, CDC25A, Survivin, PSA and TPX2 primers obtained from densitometric analysis of panel 
A.  
 
Particularly, we observed a significant variation in the level of enrichment in 
six fragments out of fourteen examinated: c-MYC, CDC25A, PSA, A2M, 
Survivin, TPX2, coding respectively for a transcription factor, for a cell-cycle 
protein phosphatase, for a kallikrein-related peptidase3, for α2-
macroglobulin, for an inhibitor of apoptosis and for a microtubule-associated 
protein. 
To study the functional effect of STAT3 on its target gene in this cell 
lines, we extracted total RNA from treated and control cells and mRNA was 
A2M 
c-MYC 
CDC25A 
Survivin 
PSA 
TPX2 
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converted to DNA by reverse transcription. The expression levels of genes 
tested by ChIP experiments was measured by real-time PCR. In Figure 27 
reports a graphical dispaly of the expression profile of the A2M, c-MYC, 
CDC25A and Survivin genes in IL-6 and H2O2 stimulated and control cells. 
The expression levels of the genes was normalized with the expression of 
GAPDH in the same sample, as reference gene. The expression profiles of 
this genes showed some differences in two cell lines and in response to 
stimulations and was compared to results obtained from densitometric 
anlaysis of the same genes. Only for A2M expression level, we did not 
observe any expression, but this can be explained by negative control that 
STAT3 can have on the promoter of this gene. 
 
 
  LNCaP              PC3 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig .27: Expression profile of A2M, c-MYC, CDC25A, Survin in LNCaP and PC3 cells untreated and stimulated 
with IL-6 and H2O2. 
 
 
 
A2M 
c-MYC 
CDC25A 
Survivin 
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4.3.1.4 Correlation between STAT3 PTMs and expression genes. 
 
Post-translational modifications (PTMs) of nuclear proteins play 
essential roles in the regulation of gene transcription and signal transduction 
pathways. We evaluated the phosphorylation, the acetylation and the 
glutathionylation with STAT3 transcriptional activity in wild-type prostate 
cancer cells and in response to cytokines and to oxidative stress.  In table 
(Figure 28) we correlated STAT3 PTMs and genes that showed greater 
differences in expression profiles obtained from ChIP and RT2-PCR 
experiments. Stat3 activation regulates genes involved in cell growth and cell 
survival, including c-Myc, Survivin, Cdc25A. Lys685 acetylation was found 
to be critical for cell cycle–related genes expression, Cdc25A and Survivin, in 
hormone-responsive LNCaP cell line. By contrast in PC3 cell line the 
glutathionylation of STAT3 was involved in the the regulation of genes. 
However, neither Tyr705 phosphorylation alone nor Lys685 acetylation 
alone seems to be sufficient for Stat3 activation, contrary to glutathionylation 
that occurs in intact PC3 cells under basal conditions and is critical for up-
regulation of Cdc25A. The simultaneus presence of both the phosphorylation 
and glutathionylation, that occurs in response to oxidative stress, had two 
different effects: in LNCaP cells all genes were down-regulated and 
particulary the c-Myc; in PC3 cells these modifications promoted the up-
regulation of Survivin compared to untreated cells. 
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LNCaP 
  
 
 
 
PC3 
 
 
 
 
 
 
 
Fig. 28: Correlations between PTMs of STAT3 and STAT3 transcriptional activity on genes that showed greater 
differences in expression profiles obtained from previous ChIP and RT2-PCR experiments in LNCaP and PC3 cell 
lines. 
 
 
 
4.3.2 B) FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUES  
 
4.3.2.1 Stat3 and its PTMs correlate with High Gleason Score. 
 
Forty-six specimens from 23 matched prostate tumor were evaluated. 
The sample FFPE analyzed consisted of one sample each from area of 
prostatic adenocarcinomas and “normal adjacent to tumors” from patients 
with different Gleason grades and TNM stage tumors. The levels of activated 
phospho-Stat3 protein and the main post-translational modifications in 
prostate tumors were detected by immunoblotting analysis, normalized with 
actin, and were correlated with more malignant tumor specimens exhibiting 
Gleason scores 6, 7 and 8 (Figures 29, 30). 
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Gleason Score 6 
 
 
 
 
 
 
 
 
  
 
 
  Gleason Score 7            Gleason Score 8 
 
 
 
 
 
 
 
 
 
Fig. 29: Western blot analysis of protein extracted from FFPE for Gleason Scores 6, 7, 8 of STAT3, pY705-STAT3, 
acK685-STAT3. For the glutathionylation we performed a double staining with a monoclonal antibody against 
protein-bound GSH and Ab STAT3. T: prostate carcinomas; N: matched normal adjacent to tumor. 
 
There was a significant correlation between levels of acetylated and 
glutathionylated Stat3 in different clinical stage (Table A). In fact we 
observed a decrease of acetylation as post-translational modification with 
more malignant tumor, by contrast an increase of glutathionylation with more 
Gleason Score. It was not possible to assess the correlation between levels of 
Stat3 and its PTMs and established parameters of disease progression (e.g., 
PSA levels after prostatectomy) because of the short time of follow-up after 
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treatment of this cohort of patients. Thus, more different PTMs of Stat3 
levels correlate well with more aggressive disease in prostate cancer as 
determined by Gleason score at the time of radical prostatectomy. 
 	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
Fig. 30: Cumulative results of STAT3 levels in tumoral prostate tissues from 23 matched prostate carcinomas. The 
data were obtained from densitometric analysis of Immunoblotting in Fig. Each bar is the average of all tumor 
samples for each Gleason Score normalized with actin, used as a reference to normalize the amount of protein 
extracts loaded. 	  	  	  	  	  	  	  
TABLE A. STAT3 Activity and Gleason Score 
 
Sample no. 
STAT3 total 
pY-STAT3 
acK-STAT3 
Glut-STAT3 
Gleason score = 6 
10 
3309 
3838 
5932 
5133 
Gleason score = 7 
8 
3031 
3002 
5591 
2691 
Gleason score = 8 
4 
2541 
3727 
2691 
8062 
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5. DISCUSSION 
 
 
STAT3 transcription factor resides at the critical junction between 
intracellular signaling events and the regulation of genes involved in many 
key cellular processes (Frank D.A., 2007). In addition, its effect mediated 
through interactions with other proteins allows it to control cellular function 
on multiple levels (German D., 2007). 
In our research we have demonstrated that STAT3 contributes to the 
activation of a novel target gene involved in oncogenic process. The high-
affinity binding site for at –4305/-4297 bp from the transcription start in 
TPX2 regulatory region is likely to be involved in this regulation. In fact, this 
site is bound in vivo by STAT3 and its sequence is identical to the well-
characterized STAT3-binding site in the CDKN1A gene. Furthermore an 
examination of the corresponding 5'-region of the mouse Tpx2 gene on 
chromosome 2 revealed the existence of a STAT consensus sequence at -
3965/-3957 base pairs. The similarity of sequences in gene-flanking regions 
in genomes of different species supports the existence of similar regulatory 
mechanisms and the intervention of the same transcription factors. The 
regulatory binding sites of the STAT proteins are often found at a short 
distance from the promoter. However, binding at high distance has also been 
described. Thus, for example, a site for STAT3 at -1093 has identified in the 
human perforin gene, and for STAT5 at -4285 in the human IL-2Rα gene. 
Considering that the BCL2L1 and the TPX2 genes have the 5’-region in 
common, it could be argued that the STAT3 site that we described might also 
regulate the expression of BCL2L1. However, it appears that constitutively 
activated STAT3 produces an increase in the transcription of the gene, 
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contributing to the over-expression of TPX2 observed in a variety of 
tumours. In this regard it should be mentioned that highly expressed TPX2 
has been detected by in hepatocellular carcinoma and in lung, prostate, 
ovarian, pancreatic and colon cancer cell lines. In all these cancer cells 
STAT3 has been found constitutively activated (Yu and Jove, 2004; Sanchez 
et al., 2003; Lin et al., 2005). 
Activated STAT3 is involved in the regulation of expression of a 
multitude of genes, but the cellular effects elicited can vary greatly 
depending on cell type and on the mechanism of activation of STAT3 itself. 
This variety of effects might be explained by many factors, such as the 
particular composition of the STAT3-multiprotein complex binding to DNA, 
the post-translational modifications of STAT3. Our finding add PARP-1 to 
the list of proteins which can associated in the nucleus with STAT3. PARPs 
constitute a family of 18 distinct enzymes catalyzing the sequential transfer 
of ADPr units, by using nicotinamide adenine dinucleotide (NAD+) as 
substrate, on to protein acceptors to produce linear and/or branched polymers 
of ADPr. The mammalian PARP-1 is the major isoform of the PARP family, 
an abundant and ubiquitous nuclear protein, that plays important roles in a 
variety of genomic processes, including the regulation of chromatin structure 
and transcription in response to specific cellular signals (Kraus W.L., 2008). 
The nuclear PARP (type I) is a 113 kDa protein and appears to be the major 
poly(ADP-ribosyl)ating activity in higher eukaryotes after DNA damage. In 
fact in the past the main interest about PARP-1 was directed to its role on 
sensing, and binding to, the damaged DNA, thus being involved in the 
process of DNA repair. But another important role of PARP-1 is its 
participation in transcription regulation, either by means of poly(ADP-
ribosyl)ation of histones with a consequent decondensation of chromatin, or 
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by its association with protein complexes which bind to enhancers or 
promoter, which can lead to an activation or repression of transcription. 
Interestingly, the some function, but in different way, is carried out by 
CBP/P300 protein, an histone acetylases protein able to modifie histone 
subunits within the core nucleosome, described as coactivator for many 
transcription factor. The association of STAT3 with the P300 coctivator it 
was largely described (Ray S., 2005; Yuan Z., 2005). Phosphorylated STAT3 
dimers recruit CBP/P300 protein, which, in turn, acetylates the NH2 terminus 
of STAT3. Finally, deacetylation of AcSTAT3 by HDACs 1 and 4 reduced 
the affinity of STAT3 for the P300 coactivators, leading to subsequent 
STAT3 dephosphorylation, ubiquitination, and/or cytoplasmatic 
redistribution. The existence of a specific order of the action of the 
histone/factor-modifying complexes implies a signaling pathway for 
mediating gene activation/repression events, and for temporal-specific 
“sensor” responding to additional signalling pathway activated/extinguished 
during the periodic time interval of coregulator exchange (Rosenfeld M.G., 
2009). Considering that we found a different set of STAT3-associated 
proteins in tumoral cell lines in which the activation of STAT3 can be 
mediated by different pathways, we can speculate not only a tumor-specific, 
but a signal-dependent composition of enhanceosome STAT3-specific. 
Particularly PARP-1 interacted with STAT3 when the transcription factor 
was phosphorylated by Src-kinases or after EGF stimulation, instead the 
association with CBP/P300 is IL-6 inducted. We have shown that PARP-1 
and P300 can affect STAT3 activity in the regulation of some target genes. 
Using ChIP we found that PARP-1 and P300 were recruited to the promoter 
of the P21Waf1, α2macroglobulin and MMP-9 genes depending on the 
stimulus. Moreover the two proteins directly regulated STAT3’s 
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transcriptional activity because a specific inhibition of PARP-1 and P300 
decreased its target genes expression by modulating its binding to the 
promoter. However, the exact mechanism by which P300 and specially 
PARP-1 regulates STAT3’s-DNA binding is still not clear, but may be 
correlated with different PTMs that these proteins can bring not only on the 
chromatin, but also on the different components of macromolecular 
complexes. In the study of STAT3 partners that affect its function, we 
demonstrated the importance of PTMs of STAT3 in prostate cancer (CaP). 
This work evaluated in parallel, by immunoblotting analysis, the variation of 
phosphorylation, acetylation and gluthationylation of STAT3 in cell lines and 
in human prostate tumor (FFPE). Our analysis demonstrates that inverse 
levels of acetylation and gluthationylation of Stat3 are associated with higher 
Gleason scores (6, 7, 8), which is indicative of more aggressive and poorly 
differentiated tumors. This observation may be valuable for identification and 
management of high-risk prostate cancer patients, especially those with high 
Gleason scores. In LNCaP and PC3 cell lines we observed how a change in 
PTMs could affect in different interaction with coactivator protein and then 
in gene expression. It can be speculate that S-gluthationylation of STAT3 and 
the recruitment, as coactivators, of ERp57 and Ref-1, two protein involved in 
redox modification, is a response to oxidative stress, associated with a more 
advanced state of disease. Moreover, recent studies indicate that IL-6 induces 
androgen receptor-mediated gene regulation through the STAT3 protein, 
raising the possibility that IL-6-induced STAT3 activation may contribute to 
the development of hormone-refractory prostate cancer. More studies would 
be required on PTMs of STAT3 and its coregulators to extend the knowledge 
about its oncogenic potential to find a viable strategy for delaying or 
preventing progression of PCa to androgen refractory state.
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